SMALL MOLECULES
Rottapharm Biotech will continue to leverage its long-standing expertise in medicinal chemistry, which has allowed the design and synthesis of more than 15000 original compounds and 19 new drugs on the market. They are covered by more than 500 patents belonging to nearly 80 patent families and are described in over 1000 peer-reviewed scientific publications.
Medicinal Chemistry expertise is focused on the management and coordination of activities within innovative preclinical projects. Experienced scientists are devoted to manage third-party scale-up activities to meet the needs of clinical development.
BIOTHERAPEUTICS
Rottapharm Biotech’s scientists have developed and patented a proprietary technology platform for the generation and selection of monoclonal antibodies against a target of choice. However, most of the current R&D efforts in biotherapeutics are focused on a new genetic platform for the local treatment of osteoarthritis.